Abridge vs Nabla
This is the most asked head to head in ambient documentation, and the two companies are running different plays. Abridge is the enterprise reference standard: Best in KLAS for Ambient AI in 2025 and 2026, the largest independent peer reviewed study in the category with 1,306 clinicians at Kaiser Permanente published in NEJM AI, and the deepest Epic integration in the index. Nabla's edge is breadth: the widest EHR footprint in the category, spanning Epic, athenahealth, Oracle Health, NextGen, and Greenway. If your failure mode is an Epic health system that needs auditable evidence and native workflow depth, start with Abridge. If your failure mode is a mixed EHR environment that one contract has to cover, start with Nabla, and confirm its data training default and BAA tier before deployment. Neither publishes pricing.
- The evidence bar decides it for you: the largest independent peer reviewed study in the category, 1,306 clinicians at Kaiser Permanente published in NEJM AI, corroborated by Best in KLAS for Ambient AI in both 2025 and 2026, which is buyer survey based rather than vendor asserted.
- Compliance needs an audit trail, not trust: Linked Evidence maps every part of a generated note back to the source audio so a clinician can verify any sentence against what was said before signing.
- You are an Epic organization buying workflow depth: Abridge is embedded natively across Haiku, Canto, and Hyperdrive with bidirectional note sync, extending into structured orders and real time prior authorization.
- You run a mixed EHR estate: integrations span Epic, athenahealth, Oracle Health, NextGen, and Greenway, the widest footprint in the category, which means one scribe contract instead of several.
- Your deployment profile matches its base: reported across more than 85,000 clinicians at over 150 organizations, weighted toward hospital systems, emergency departments, and multi provider groups.
- You want published efficiency figures tied to peer review: the vendor attributes roughly 55 percent of users saving at least an hour a day and a 27 percent reduction in burnout to a published NEJM study.
Side-by-Side
| Axis | A Abridge |
N Nabla |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | — | |
| Model and Technology Transparency | — | — |
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | — | |
| HIPAA and BAA Posture | — | |
| Security Certifications and Trust Center | — | — |
| FDA and Regulatory Status | — | — |
| AI Governance and Bias Disclosure | — | — |
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | — | — |
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Deployment counts, language totals, and efficiency figures for both vendors are vendor published and have not been independently validated by this index. Abridge's evidence grade reflects the scale and venue of the Kaiser Permanente study, not a re verification of its findings. Two Nabla capability records carry procurement caveats: session data is reported as used for model training by default, and the free tier reportedly does not include a Business Associate Agreement; confirm both contractually before deployment. Neither company publishes pricing. Abridge is enterprise only with a third party estimate near $2,500 per clinician per year recorded as an estimate; Nabla has moved off previously published tiers toward a contract sales motion.